Volume Spike: Nektar Therapeutics (NKTR)

Posted in General 
May 14th, 2009

Nektar Therapeutics (Nasdaq: NKTR) has confirmed that the FDA has approved Cimzia® for the treatment of adult patients with moderately to severely active rheumatoid arthritis.  Shares are suring and are up 12% at $5.69 as of 9:55 AM EST on some 660,000 shares.  That is actually just over a full day’s average daily volume, and it is only 9:55 AM EST.  52-WEEK TRADING RANGE IS $2.45 to $6.25.     -JON C. OGG

Comments are closed